Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
We are still only in January and Celgene and Sanofi have already made a combined $20B in M&A deals.
Now insiders say J&J has decided it is no longer interested.
The surprising disclosure was outlined in a November 2017 letter from the FDA.
KaNDy Therapeutics is a clinical-stage company that is focused on female sex-hormone related conditions.
The company struck the cash-and-share deals to boost its presence in Europe.
News of the buy was tucked away in the company’s fourth-quarter financial report.
This acquisition strategy is part of its two-pronged approach to growth, along with internal R&D.
The company’s Luye Medical Group unit plans to evaluate proposals from investment banks as soon as next month, according to the people.
Novo has tried to apply pressure, but the ABLX board and principal shareholder have not been moved.
Here are five possible acquisition targets to keep an eye on.